Alkermes plc (ALKS)
-NasdaqGS 32.07 
0.38(1.20%) 11:22AM EDT - Nasdaq Real Time Price
| Prev Close: | 31.69 |
|---|
| Open: | 31.59 |
|---|
| Bid: | 32.49 x 300 |
|---|
| Ask: | 32.52 x 500 |
|---|
| 1y Target Est: | 28.45 |
|---|
| Beta: | 1.21 |
|---|
| Next Earnings Date: | 23-May-13 |
|---|
| Day's Range: | 31.59 - 33.04 |
|---|
| 52wk Range: | 14.82 - 33.04 |
|---|
| Volume: | 1,094,337 |
|---|
| Avg Vol (3m): | 1,307,090 |
|---|
| Market Cap: | 4.27B |
|---|
| P/E (ttm): | N/A |
|---|
| EPS (ttm): | -0.32 |
|---|
| Div & Yield: | N/A (N/A) |
|---|
The broker you select will become the default broker for Trade Now
Quotes delayed, except where indicated otherwise. Currency in USD.
Headlines
- Alkermes Stock Hits New 52-Week High (ALKS)at TheStreet(Mon 10:09AM EDT)
- Biogen's Hemophilia BLA AcceptedZacks(Mon 9:40AM EDT)
- Alkermes to Host Conference Call to Discuss Financial Results for Fiscal Year 2013Business Wire(Thu, May 16)
- SGEN's Adcetris under FDA ReviewZacks(Thu, May 16)
- Alkermes Elects Nancy Wysenski to Board of DirectorsBusiness Wire(Thu, May 16)
- ALKERMES PLC. Files SEC form 8-K, Change in Directors or Principal Officers, Financial Statements and ExhibitsEDGAR Online(Thu, May 16)
- Cempra/Toyama Ink DealZacks(Wed, May 15)
- Much Awaited Test Launch by GenomicZacks(Wed, May 15)
- Myriad Soars Higher on Celeb CloutZacks(Wed, May 15)
- Isis Gets $3.5M Milestone PaymentZacks(Tue, May 14)
- SALT 2013: The 5 Best Ideas of the Year Aheadat TheStreet(Fri, May 10)
- 6 Superstars For Your Biotech Portfolio: John McCamantat Seeking Alpha(Fri, May 10)
- Alkermes' CEO Presents at Bank of America Merrill Lynch Smid Cap Conference (Transcript)at Seeking Alpha(Wed, May 8)
- Learn Which Antibody Companies Show Show a Higher Probability of Success; Antibodies Have a Higher Track Record of M&A and More Predictable Toxicology ProfileWall Street Transcript(Fri, May 3)
- Alkermes’ Corporate Presentation to be Webcast at the Bank of America Merrill Lynch 2013 Smid Cap ConferenceBusiness Wire(Wed, May 1)
Key Statistics
| Forward P/E (1 yr): | 28.51 |
|---|
| P/S (ttm): | 7.78 |
|---|
| Ex-Dividend Date: | N/A |
|---|
Analysts
| Annual EPS Est
(Mar-13)
: | 1.08 |
|---|
| Quarterly EPS Est
(Mar-13)
: | 0.17 |
|---|
| Mean Recommendation*: | 2.3 |
|---|
| PEG Ratio (5 yr expected): | 0.36 |
|---|
Business Summary
Alkermes Public Limited Company, an integrated biopharmaceutical company, develops medicines that enhance patient outcomes. The company offers RISPERDAL CONSTA for schizophrenia and bipolar I disorder; INVEGA SUSTENNA for the treatment of schizoph...
View More